Optimizing combination chemotherapy by controlling drug ratios

Molecular Interventions

Volumn 7, Issue 4, 2007, Pages 216-223

  Mayer, Lawrence D ^a   Janoff, Andrew S ^b  

^a Celator Pharmaceuticals Corp   (Canada)

^b Celator Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CISPLATIN; CPX 1; CYTARABINE; DAUNORUBICIN; FLOXURIDINE; IRINOTECAN; LIPOSOME; PACLITAXEL; PLATINUM DERIVATIVE; POLYGLUTAMIC ACID; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CULTURE; CONCENTRATION RESPONSE; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SOLUBILITY; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; LIPOSOMES; NEOPLASMS;

EID: 34548759797     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.7.4.8     Document Type: Review

References (31)

1. Ramaswamy, S. Rational design of cancer-drug combinations. N. Eng. J. Med. 357, 299-300 (2007).
2. Zimmerman, G.R., Lehar, J., and Keith, C.T. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Disc. Today 12, 34-42 (2007).
3. Frei, E. III. Clinical studies of combination chemotherapy for cancer, in Synergism and Antagonism in Chemotherapy ( Chou, T.C. and Rideout, D.C., eds) Pp 103-108, Academic Press, California (1991).
4. DeVita, V.T. Jr. Principles of cancer management: Chemotherapy, in CANCER: Principles & Practice of Oncology (DeVita, V.T. Jr., Hellman, S. and Rosenberg, S.A., eds). Vol 1. pp 333-347, Lippincott-Raven, Philadelphia (1997).
5. Delbaldo, C., Michiels, S., Syz, N., Soria, J., Le Chevalier, T., and Pignon, J. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer. JAMA 292, 470-484 (2004).
6. Breathnach, O.S., Freidlin, B., Conley, B., Green, M.R., Johnson, D.H., Gandara, D.R., O'Connell, M., Shepherd, F.A., and Johnson, B.E. Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: Sobering results. J. Clin. Oncol. 19, 1734-1742 (2001).
7. rd edition, volume III (Gregoriadis, G., ed.), pp 25-48, Informa Healthcare (2007).
8. Mayer, L.D., Harasym, T.O., Tardi, P.G., Harasym, N.L., Shew, C.R., Johnstone, S.A., Ramsay, E.C., Bally, M.B., and Janoff, A.S. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5, 1854-1863 (2006).
9. Borisy, A.A., Elliot, P.J., Hurst, N.W., Lee, M.S., Lehar, J., Price, E.R., Serbedzija, G., Zimmermann, G.R., Foley, M.A., Stockwell, B.R. and Keith, C.T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA 100, 7977-7982 (2003).
10. Greco, W.R., Bravo, G., and Parsons, J. The search for synergy: A critical review from a response surface perspective. Pharmacol. Rev. 47, 332-385 (1995).
11. Chou, T.C. and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul. 22, 27-55 (1984).
12. Chou, T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
13. Kanzawa, F., Koizumi, F., Koh, Y. et al. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin. Cancer Res. 7, 202-209 (2001).
14. Raitanen, M., Rantanen, V., Kulmala, J., Helenius, H., Grenman, R., and Grenman, S. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. Int. J. Cancer 100, 238-243 (2002).
15. Johnston, J.S., Johnson, A., Gan, Y., Guillaume Wientjes, M., and Au, LS. Synergy between 3′-Azido-3′-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharmaceut. Res. 20, 957-961 (2003).
16. Aung, T.T., Davis, M.A., Ensminger, W.D., and Lawrence, T.S. Interaction between gemcitabine and mitomycin-C in vitro. Cancer Chemother. Pharmacol. 45, 38-42 (2000).
17. Pavillard, V., Kherfellah, D., Richard, S., Robert, J., and Montaudon, D. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br. J. Cancer 85,1077-1083 (2001).
18. Bjornsti, M.A. and Houghton, P.J. The TOR pathway: A target for cancer therapy. Nat. Rev. Cancer 4, 335-348 (2004).
19. Adam J. The proteosome: A suitable antineoplastic target. Nat. Rev. Cancer 4, 349-360 (2004).
20. Higby, D.J., Wallace, H.J., and Holland, J.F. Cis- diamminedichloroplatinum (NSC-119875): A phase I study. Cancer Chemother. Rep. 57, 459-463 (1973).
21. Ohtsu, T., Sasaki, Y., Tamura, T., Miyata, Y., Nakanomyo, H., Nishiwaki, Y., and Saijo, N. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin. Cancer Res. 6, 599-606 (1995).
22. Allen, T.M. and Cullis, P.R. Drug delivery systems: Entering the mainstream. Science 303, 1818-1822 (2004).
23. Torchilin, V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9, E128-E147 (2007).
24. nd edition (Bumitriu, S. ed.) pp. 783-822, Marcel Dekker, Inc., New York, (2002).
25. Kratz F., Abu, A.K. and Warnecke, A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Investig. Drugs, 16, 1037-1058 (2007).
26. Bonomi, P. Paclitaxel poliglumex (PPX, CT2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 7, 415-422 (2007).
27. Tardi, P.G., Gallagher, R.C., Johnstone, S., Harasym, N., Webb, M., Bally, M.B. and Mayer, L.D. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim. Biophys. Acta. 1768, 678-687 (2007).
28. Guichard, S., Cussac, D., Hennebelle, I., Bugat, R. and Canal, P. Sequence-dependent activity of the irinotecan-5-FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int. J. Cancer 73, 729-734 (1997).
29. Harasym, T.O., Tardi, P.G., Harasym, N.L., Harvie, P., Johnstone, S.A. and Mayer, L.D. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol. Res. In press.
30. Batist, G., Chi, K., Miller, W., Chia, S., Hasanbasic, F., Fisic, A., Mayer, L., Swenson, C., Janoff, A. and Gelmon, K. Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors. J. Clin. Oncol. 24, 82s (2006).
31. Batist, G., Miller, W., Mayer, L., Janoff, A., Swenson, C., Louie, A., Chi, K., Chia, S., and Gelmon, K. Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy. J. Clin. Oncol. 25, 109s, (2007).